PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)
- Citation:
- J Clin Oncol vol 38 (15_suppl) TPS5100
- Meeting Instance:
- ASCO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- GU
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Bristol-Myers & Exelixis
- Grants:
- UG1CA189823, U24CA196171
- Corr. Author:
- Authors:
- Tian Zhang Karla Ballman Atish Choudhury Ronald C. Chen Colleen Watt Yujia Wen Ardaman Shergill Tyler Zemla Hamid Emamekhoo Ulka Vaishampayan Michael J. Morris Daniel J. George Toni K. Choueiri
- Networks:
- KANSAS, LAPS-IL057, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-TX011, LAPS-WI020
- Study
- Alliance-A031704
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: